Amarin Corp. PLC ADR | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
165,744.80
56,135.40
114,987.60
85,753.90
68,592.60
116,248.10
Depreciation, Depletion & Amortization
889.40
840.60
810.50
777.60
715.60
667.90
Other Funds
360.00
888.40
-
675.30
2,796.70
20,953.50
Funds from Operations
176,504.50
93,577.90
96,532.30
63,044.70
40,209.50
94,626.70
Changes in Working Capital
13,279.40
21,562.20
12,669.20
8,274.50
7,020.50
83.90
Net Operating Cash Flow
189,783.90
72,015.70
83,863.20
71,319.20
33,189.10
94,542.90
Capital Expenditures
14.00
-
27.90
20.90
12.10
Net Investing Cash Flow
14.00
-
27.90
20.90
12.10
Issuance/Reduction of Debt, Net
10.00
2,505.80
16,228.50
-
-
Net Financing Cash Flow
121,269.20
332.60
71,336.70
62,690.20
8,323.30
Net Change in Cash
68,528.60
71,683.00
12,554.40
8,649.90
24,877.90
Free Cash Flow
189,797.80
72,015.70
83,891.10
71,340.10
33,201.20
Deferred Taxes & Investment Tax Credit
3,424.00
3,599.30
4,244.00
8,737.30
11,200.80
-
Change in Capital Stock
121,639.10
1,950.10
87,565.20
63,365.50
644.80

About Amarin Corp.

View Profile
Address
2 Pembroke House
Dublin Dublin 2
Ireland
Employees -
Website http://amarincorp.com
Updated 07/08/2019
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It's product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale.